Description

Elliott Is Circling Bio-Rad: Can This Fallen Healthcare Giant Wake Up?

Bio-Rad Laboratories has suddenly become one of the most interesting activist stories in healthcare. Elliott Investment Management has reportedly built a sizable stake in the life-science tools and diagnostics company after a brutal stock-market decline that erased more than 70% of Bio-Rad’s value from its pandemic-era peak. The setup is easy to understand: a once-prized healthcare supplier is now trading far below its former highs, its margins are under pressure, and its investment in Sartorius is worth billions. But this is not a simple turnaround story. Bio-Rad is also dealing with weak academic research demand, disruption in the Middle East, slower diagnostics momentum, and a family-controlled voting structure that could limit how quickly an activist can force change.